#AAN2022 - ND0612 Fares Well in BeyoND Trial for Parkinsons - Parkinson's News Today
4/5/2022 12:00:00 AM3 yearsago
by Marisa Wexler
by Marisa Wexler
ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson's patients, new data show. Findings reveal…
ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical t… [+3957 chars]
full article...